Patents by Inventor Eugene Yuanjin Rui

Eugene Yuanjin Rui has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11964978
    Abstract: Provided herein are compounds of the general formula (I): and pharmaceutically acceptable salts thereof, processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.
    Type: Grant
    Filed: March 11, 2022
    Date of Patent: April 23, 2024
    Assignee: PFIZER INC.
    Inventors: Ketan Satish Gajiwala, Chan Woo Huh, Mehran Jalaie, Ryan Lloyd Patman, Eugene Yuanjin Rui, Jianmin Sun, Martin James Wythes
  • Publication number: 20230382932
    Abstract: Compounds of the general formula (I): or a pharmaceutically acceptable salt thereof, processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.
    Type: Application
    Filed: July 24, 2023
    Publication date: November 30, 2023
    Applicant: PFIZER INC.
    Inventors: Martin James WYTHES, Indrawan James MCALPINE, Ryan PATMAN, Eugene Yuanjin RUI, Andrew FENSOME, Andreas MADERNA, Mehran JALAIE, Ketan S. GAJIWALA
  • Publication number: 20220324872
    Abstract: This invention relates to compounds of general Formula (I) and pharmaceutically acceptable salts thereof, in which R1, R2, R2A, R2B, R3, R4, R5A, R5B, R6, R7, R8, R9, p, q and r are as defined herein, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.
    Type: Application
    Filed: June 15, 2022
    Publication date: October 13, 2022
    Applicant: Pfizer Inc.
    Inventors: Douglas Carl Behenna, Ping Chen, Kevin Daniel Freeman-Cook, Robert Louis Hoffman, Mehran Jalaie, Asako Nagata, Sajiv Krishnan Nair, Sacha Ninkovic, Martha Alicia Ornelas, Cynthia Louise Palmer, Eugene Yuanjin Rui
  • Publication number: 20220306641
    Abstract: Provided herein are compounds of the general formula (I): and pharmaceutically acceptable salts thereof, processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.
    Type: Application
    Filed: March 11, 2022
    Publication date: September 29, 2022
    Applicant: PFIZER INC.
    Inventors: Ketan Satish GAJIWALA, Chan Woo HUH, Mehran JALAIE, Ryan Lloyd PATMAN, Eugene Yuanjin RUI, Jianmin SUN, Martin James WYTHES
  • Patent number: 11396512
    Abstract: This invention relates to compounds of general Formula (I) and pharmaceutically acceptable salts thereof, in which R1, R2, R2A, R2B, R3, R4, R5A, R5B, R6, R7, R8, R9, p, q and r are as defined herein, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.
    Type: Grant
    Filed: August 27, 2020
    Date of Patent: July 26, 2022
    Assignee: Pfizer Inc.
    Inventors: Douglas Carl Behenna, Ping Chen, Kevin Daniel Freeman-Cook, Robert Louis Hoffman, Mehran Jalaie, Asako Nagata, Sajiv Krishnan Nair, Sacha Ninkovic, Martha Alicia Ornelas, Cynthia Louise Palmer, Eugene Yuanjin Rui
  • Patent number: 11203594
    Abstract: This invention relates to compounds of general Formula I in which A, R1, R2, R3 and R4 are as defined herein, and the pharmaceutically acceptable salts thereof; to pharmaceutical compositions comprising such compounds and salts; to methods of using such compounds, salts and compositions for treating pulmonary hypertension and related diseases, like pulmonary arterial hypertension; to methods of using such compounds, salts and compositions for treating abnormal cell growth, such as cancer; and to processes to make such compounds, salts and compositions.
    Type: Grant
    Filed: April 15, 2020
    Date of Patent: December 21, 2021
    Assignee: Pfizer Inc.
    Inventors: Samit Kumar Bhattacharya, Douglas Carl Behenna, Kimberly O. Cameron, Ping Chen, John M. Curto, Kevin Daniel Freeman-Cook, Mehran Jalaie, Robert Steven Kania, Yajing Lian, Sajiv Krishnan Nair, Cynthia Louise Palmer, Martin Youngjin Pettersson, Eugene Yuanjin Rui, Matthew Sammons, Qingyi Yang, Liying Zhang
  • Publication number: 20210230196
    Abstract: Compounds of the general formula (I): or a pharmaceutically acceptable salt thereof, processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.
    Type: Application
    Filed: March 3, 2021
    Publication date: July 29, 2021
    Applicant: Pfizer Inc.
    Inventors: Martin James Wythes, Indrawan James McAlpine, Ryan Patman, Eugene Yuanjin Rui, Andrew Fensome, Andreas Maderna, Mehran Jalaie, Ketan S. Gajiwala
  • Patent number: 10968242
    Abstract: Compounds of the general formula (I): or a pharmaceutically acceptable salt thereof, processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.
    Type: Grant
    Filed: December 4, 2019
    Date of Patent: April 6, 2021
    Assignee: Pfizer Inc.
    Inventors: Martin James Wythes, Indrawan James McAlpine, Ryan Patman, Eugene Yuanjin Rui, Andreas Maderna, Mehran Jalaie, Ketan S. Gajiwala
  • Publication number: 20210087180
    Abstract: Compounds of the general formula (I): or a pharmaceutically acceptable salt thereof, processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.
    Type: Application
    Filed: September 23, 2020
    Publication date: March 25, 2021
    Applicant: PFIZER INC.
    Inventors: Ryan PATMAN, Martin James WYTHES, Eugene Yuanjin RUI, Indrawan James MCALPINE, Andrew FENSOME, Mehran JALAIE, Ketan S. GAJIWALA, Chan Woo HUH, Tuan Phong TRAN, Lei ZHANG, Dahui ZHOU, Ethan Lawrence FISHER
  • Publication number: 20200392142
    Abstract: This invention relates to compounds of general Formula (1) and pharmaceutically acceptable salts thereof, in which R1, R2, R2A, R2B, R3, R4, R5A, R5B, R6, R7, R8, R9, p, q and r are as defined herein, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.
    Type: Application
    Filed: August 27, 2020
    Publication date: December 17, 2020
    Applicant: Pfizer Inc.
    Inventors: Douglas Carl Behenna, Ping Chen, Kevin Daniel Freeman-Cook, Robert Louis Hoffman, Mehran Jalaie, Asako Nagata, Sajiv Krishnan Nair, Sacha Ninkovic, Martha Alicia Ornelas, Cynthia Louise Palmer, Eugene Yuanjin Rui
  • Publication number: 20200331909
    Abstract: This invention relates to compounds of general Formula I in which A, R1, R2, R3 and R4 are as defined herein, and the pharmaceutically acceptable salts thereof; to pharmaceutical compositions comprising such compounds and salts; to methods of using such compounds, salts and compositions for treating pulmonary hypertension and related diseases, like pulmonary arterial hypertension; to methods of using such compounds, salts and compositions for treating abnormal cell growth, such as cancer; and to processes to make such compounds, salts and compositions.
    Type: Application
    Filed: April 15, 2020
    Publication date: October 22, 2020
    Applicant: Pfizer Inc.
    Inventors: Samit Kumar Bhattacharya, Douglas Carl Behenna, Kimberly O. Cameron, Ping Chen, John M. Curto, Kevin Daniel Freeman-Cook, Mehran Jalaie, Robert Steven Kania, Yajing Lian, Sajiv Krishnan Nair, Cynthia Louise Palmer, Martin Youngjin Pettersson, Eugene Yuanjin Rui, Matthew Sammons, Qingyi Yang, Liying Zhang
  • Patent number: 10800783
    Abstract: This invention relates to compounds of general Formula (I) and pharmaceutically acceptable salts thereof, in which R1, R2, R2A, R2B, R3, R4, R5A, R5B, R6, R7, R8, R9, p, q and r are as defined herein, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.
    Type: Grant
    Filed: January 17, 2019
    Date of Patent: October 13, 2020
    Assignee: Pfizer Inc.
    Inventors: Douglas Carl Behenna, Ping Chen, Kevin Daniel Freeman-Cook, Robert Louis Hoffman, Mehran Jalaie, Asako Nagata, Sajiv Krishnan Nair, Sacha Ninkovic, Martha Alicia Ornelas, Cynthia Louise Palmer, Eugene Yuanjin Rui
  • Patent number: 10709709
    Abstract: Compounds of the general formula): processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.
    Type: Grant
    Filed: December 18, 2018
    Date of Patent: July 14, 2020
    Assignee: Pfizer Inc.
    Inventors: John Howard Tatlock, Indrawan James McAlpine, Michelle Bich Tran-Dube, Eugene Yuanjin Rui, Martin James Wythes, Robert Arnold Kumpf, Michele Ann McTigue, Ryan Patman
  • Publication number: 20200102334
    Abstract: Compounds of the general formula (I): or a pharmaceutically acceptable salt thereof, processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.
    Type: Application
    Filed: December 4, 2019
    Publication date: April 2, 2020
    Applicant: Pfizer Inc.
    Inventors: Martin James Wythes, Indrawan James McAlpine, Ryan Patman, Eugene Yuanjin Rui, Andrew Fensome, Andreas Maderna, Mehran Jalaie, Ketan S. Gajiwala
  • Patent number: 10538542
    Abstract: Compounds of the general formula (I): or a pharmaceutically acceptable salt thereof, processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.
    Type: Grant
    Filed: March 11, 2019
    Date of Patent: January 21, 2020
    Assignee: Pfizer Inc.
    Inventors: Martin James Wythes, Indrawan James McAlpine, Ryan Patman, Eugene Yuanjin Rui, Andrew Fensome, Andreas Maderna, Mehran Jalaie, Ketan S. Gajiwala
  • Patent number: 10428104
    Abstract: Compounds such as: processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds to treat neoplasms have been disclosed.
    Type: Grant
    Filed: February 17, 2016
    Date of Patent: October 1, 2019
    Assignee: Pfizer Inc.
    Inventors: John Howard Tatlock, Indrawan James McAlpine, Michelle Bich Tran-Dube, Eugene Yuanjin Rui, Martin James Wythes, Robert Arnold Kumpf, Michele Ann McTigue
  • Publication number: 20190284216
    Abstract: Compounds of the general formula (I): or a pharmaceutically acceptable salt thereof, processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.
    Type: Application
    Filed: March 11, 2019
    Publication date: September 19, 2019
    Applicant: Pfizer Inc.
    Inventors: Martin James Wythes, Indrawan James McAlpine, Ryan Patman, Eugene Yuanjin Rui, Andrew Fensome, Andreas Maderna, Mehran Jalaie, Ketan S. Gajiwala
  • Publication number: 20190135817
    Abstract: This invention relates to compounds of general Formula (I) and pharmaceutically acceptable salts thereof, in which R1, R2 , R2A , R2B, R3, R4, R5A, R5B, R6, R7, R8, R9, p, q and r are as defined herein, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.
    Type: Application
    Filed: January 17, 2019
    Publication date: May 9, 2019
    Applicant: Pfizer Inc.
    Inventors: Douglas Carl Behenna, Ping Chen, Kevin Daniel Freeman-Cook, Robert Louis Hoffman, Mehran Jalaie, Asako Nagata, Sajiv Krishnan Nair, Sacha Ninkovic, Martha Alicia Ornelas, Cynthia Louise Palmer, Eugene Yuanjin Rui
  • Publication number: 20190111060
    Abstract: Compounds of the general formula): processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.
    Type: Application
    Filed: December 18, 2018
    Publication date: April 18, 2019
    Applicant: Pfizer Inc.
    Inventors: John Howard Tatlock, Indrawan James McAlpine, Michelle Bich Tran-Dube, Eugene Yuanjin Rui, Martin James Wythes, Robert Arnold Kumpf, Michele Ann McTigue, Ryan Patman
  • Patent number: 10246433
    Abstract: This invention relates to compounds of general formula (I) in which R1, R2, U, V, L, M, R5, m, X, Y and Z are as defined herein, and the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.
    Type: Grant
    Filed: May 3, 2017
    Date of Patent: April 2, 2019
    Assignee: Pfizer Inc.
    Inventors: Martin Paul Edwards, Robert Arnold Kumpf, Pei-Pei Kung, Indrawan James McAlpine, Sacha Ninkovic, Eugene Yuanjin Rui, Scott Channing Sutton, John Howard Tatlock, Martin James Wythes, Luke Raymond Zehnder